What is the appropriate heparin dosing for stroke prophylaxis in atrial fibrillation?

Heparin is NOT recommended for long-term stroke prophylaxis in atrial fibrillation

Oral anticoagulation with warfarin (INR 2.0-3.0) or direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, or apixaban are the recommended therapies for stroke prevention in AF—not heparin. 1

Why Heparin is Not Used for Chronic Stroke Prevention

Heparin (both unfractionated and low-molecular-weight) has no role in long-term stroke prophylaxis for atrial fibrillation. The 2014 AHA/ACC/HRS guidelines explicitly state that oral anticoagulants are the Class I recommendation for patients with nonvalvular AF and CHA₂DS₂-VASc score ≥2. 1 Heparin is reserved only for specific short-term bridging situations, not chronic prevention.

When Heparin IS Appropriately Used in AF

Heparin has limited, specific indications in AF management:

1. Bridging Therapy During Warfarin Interruption

• For mechanical heart valves: Bridging with UFH or LMWH is recommended when warfarin must be interrupted for procedures 1
• For non-valvular AF: Bridging decisions should balance stroke vs. bleeding risk—not automatically indicated 1
• The 2001 guidelines suggest heparin may be held for up to 1 week for procedures in non-valve patients without substitution 2

2. Peri-Cardioversion Anticoagulation

When cardioversion is needed:

• AF <48 hours duration: May proceed with immediate cardioversion under heparin cover (IV bolus followed by infusion to aPTT 1.5-2.0 times control), then transition to oral anticoagulation for ≥4 weeks 2, 3

• AF >48 hours or unknown duration: Either:

  • Anticoagulate with warfarin (INR 2.0-3.0) for 3-4 weeks pre-cardioversion, give heparin during procedure, continue warfarin ≥4 weeks post-cardioversion 2
  • OR use TEE-guided approach: if no thrombus, give heparin immediately before cardioversion, then continue oral anticoagulation ≥4 weeks 3

Specific dosing for peri-cardioversion: Initial IV bolus followed by continuous infusion adjusted to aPTT 1.5-2.0 times control 2. The FDA label suggests initial 5,000 unit IV bolus followed by 20,000-40,000 units/24 hours continuous infusion 4.

3. Acute Ischemic Stroke with AF

The evidence here is negative—heparin does NOT improve outcomes:

• The International Stroke Trial (3,169 AF patients) showed subcutaneous heparin (5,000 or 12,500 units BID) reduced early recurrent ischemic stroke slightly (4.9% to 2.3%) but increased hemorrhagic stroke (0.4% to 2.8%) with no net benefit on death or dependency 5
• No net advantage to heparin treatment in acute stroke with AF 5
• Current practice favors early initiation of DOACs rather than heparin bridging 6

The Correct Long-Term Approach

For stroke prophylaxis in AF, use risk stratification then oral anticoagulation:

1. Calculate CHA₂DS₂-VASc score 1

2. CHA₂DS₂-VASc ≥2: Oral anticoagulation required

   • First-line options: Warfarin (INR 2.0-3.0), dabigatran, rivaroxaban, or apixaban 1
   • DOACs preferred over warfarin in most patients due to superior safety/efficacy profile 7

3. CHA₂DS₂-VASc = 1: Consider oral anticoagulation or aspirin 1

4. CHA₂DS₂-VASc = 0: Reasonable to omit antithrombotic therapy 1

5. Mechanical heart valves: Warfarin mandatory (INR 2.0-3.0 or 2.5-3.5 depending on valve type/location) 1

Critical Pitfalls to Avoid

• Do not use heparin as chronic stroke prevention—it requires continuous monitoring, hospitalization, and has no proven long-term efficacy for this indication
• Do not routinely bridge all AF patients undergoing procedures—only those at highest stroke risk (mechanical valves, recent stroke/TIA) clearly benefit 1
• Do not use heparin in acute AF stroke expecting benefit—the evidence shows harm outweighs benefit 5
• In patients unable to take oral anticoagulants, aspirin is the alternative—not long-term heparin 1